Previous 10 | Next 10 |
By Vinay Thapar and Frank Caruso US healthcare is always a political hot potato, and volatility is expected to rise as the November elections approach. But investors can find good opportunities in the sector in companies with strong long-term business drivers that are relatively immune to ...
By Michelle Borré, CFA, Head of Fundamental Alternative Strategies , and Brian Giesen, CFA, Intermediate Research Analyst Restrictions on the pricing of drugs delivered in doctors' offices and hospitals could have significant investment implications. The Trump Administration is...
It's time to talk about a new venture called EQRx. This has made quite a splash in the last few days at the JPMorgan investor conference, and it's been launched by Alexis Borisy (involved with founding and/or helping run CombinatoRx, Foundation, Blueprint, WarpDrive Bio, Editas, Relay, and oth...
Success is not final; failure is not fatal: it is the courage to continue that counts. - Winston Churchill Not all companies are scared of a drug losing patent protection. Generics are drugs identical in chemical composition to the original medicines, and hence, rely heavily on the e...
Look to the nervous system as the key to maximum health. - Galen The US is the largest manufacturer and consumer of pharmaceuticals and spends the most on research & development. The most logical result follows. American companies are fetching the most revenues from around the worl...
By Stephen H. Dover, CFA, Executive Vice President, Head of Equities, Krzysztof Musialik, CFA, Research Analyst, Franklin Templeton Emerging Markets Equity, and Steve Kornfeld, CFA, Portfolio Manager, Research Analyst, Franklin Equity Group The biopharma industry has the potential to save...
By Andy Acker, CFA & Luyi Guo, Ph.D., CFA & Rich Carney, CFA Last week, the Trump administration abandoned plans to overhaul drug rebates in Medicare while a federal judge ruled against listing prescription drug prices in TV ads. But U.S. drug reform is far from over, with implica...
By Stephen H. Dover, Executive Vice President, Head of Equities; Aman Gupta, Portfolio Manager, Research Analyst, Franklin Mutual Series; Brian DeChristopher, Research Analyst, Franklin Equity Group; Evan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group; Krzysz...
By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...
By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...
News, Short Squeeze, Breakout and More Instantly...
First Trust Nasdaq Pharmaceuticals ETF Company Name:
FTXH Stock Symbol:
NASDAQ Market:
2024-07-11 17:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-21 06:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-01 11:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...